[{"id":"90e81d8f-a3af-400e-8588-9771bd129184","acronym":"","url":"https://clinicaltrials.gov/study/NCT02429375","created_at":"2021-01-18T11:37:23.247Z","updated_at":"2024-07-02T16:36:10.537Z","phase":"Phase 1/2","brief_title":"Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT02429375","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" TNFRSF8 • CD4","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin) • mocetinostat (MGCD0103)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 04/22/2015","start_date":" 04/22/2015","primary_txt":" Primary completion: 02/17/2021","primary_completion_date":" 02/17/2021","study_txt":" Completion: 02/17/2021","study_completion_date":" 02/17/2021","last_update_posted":"2022-05-12"},{"id":"ef479cbf-c976-417b-a2ca-e29c70b6fea5","acronym":"PRIMED-001","url":"https://clinicaltrials.gov/study/NCT02993991","created_at":"2021-01-18T14:43:45.398Z","updated_at":"2025-02-25T14:37:04.085Z","phase":"Phase 1","brief_title":"Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity","source_id_and_acronym":"NCT02993991 - PRIMED-001","lead_sponsor":"University Health Network, Toronto","biomarkers":" PD-L1 • CD8 • CD4","pipe":" | ","alterations":" CD8 positive","tags":["PD-L1 • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • mocetinostat (MGCD0103)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/10/2017","start_date":" 10/10/2017","primary_txt":" Primary completion: 12/21/2017","primary_completion_date":" 12/21/2017","study_txt":" Completion: 12/21/2017","study_completion_date":" 12/21/2017","last_update_posted":"2017-12-29"},{"id":"31d296d6-c602-4136-a441-fbf10e081e62","acronym":"","url":"https://clinicaltrials.gov/study/NCT02236195","created_at":"2021-01-18T10:29:33.978Z","updated_at":"2024-07-02T16:37:18.220Z","phase":"Phase 2","brief_title":"Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes","source_id_and_acronym":"NCT02236195","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" CREBBP","pipe":"","alterations":" ","tags":["CREBBP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • mocetinostat (MGCD0103)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 07/01/2016","study_completion_date":" 07/01/2016","last_update_posted":"2017-09-01"}]